Global $5.42 Bn Anti-Obesity Drugs Markets to 2030: Focus on Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies

News provided by

Aug 31, 2021, 12:00 ET

DUBLIN, Aug. 31, 2021 /PRNewswire/ -- The "Antiobesity Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

The global antiobesity market is expected to grow from $1.46 billion in 2020 to $2.4 billion in 2021 at a compound annual growth rate (CAGR) of 64.4%. The market is expected to reach $5.42 billion in 2025 at a CAGR of 22.6%.

Major players in the anti-obesity drugs market are F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Pfizer Inc.

The anti-obesity drugs market consists of sales of anti-obesity drugs and related services. This industry includes establishments that produce pharmacological agents that reduce or control overweight.

Obesity is a major health problem worldwide which is caused from leading a sedentary lifestyle and consumption of unhealthy food. Though various anti-obesity drugs have been approved and are available in the USA, European Union, Australia, and Japan to treat obesity and overweight. It has been observed that these drugs have various adverse effects on patients undergoing treatment for obesity.

Adverse effects include low blood pressure and blood glucose, incontinence, insomnia, nausea, diarrhea and others. For instance, Sibutramine and its combination drugs sold under various brands was recalled in various countries due to various side effects including heart attack in consumers. These factors restraint the growth of anti-obesity drugs market.

Pharmaceutical industry is witnessing an increase in the number of mergers and acquisition among companies developing drugs for metabolic disorders such as obesity, diabetes and others. This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market.

Obesity is a major public health concern globally. Globally, prevalence rate of obesity is increasing every year. According to WHO, more than 1.9 billion adults over the age of 18 years were overweight of which over 650 million were obese and 38 million children under the age of 5 were overweight or obese in 2019.

This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity and lack of awareness on the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving market growth.

Key Topics Covered:

1. Executive Summary

2. Anti-obesity Drugs Market Characteristics

3. Anti-obesity Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Anti-obesity Drugs

5. Anti-obesity Drugs Market Size And Growth
5.1. Global Anti-obesity Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Anti-obesity Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Anti-obesity Drugs Market Segmentation
6.1. Global Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Peripherally acting anti obesity drugs
Centrally acting anti obesity drugs

6.2. Global Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Prescription Drugs (Rx)
OTC Drugs

6.3. Global Anti-obesity Drugs Market, Segmentation By Medication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Monotherapies
Polytherapies

7. Anti-obesity Drugs Market Regional And Country Analysis
7.1. Global Anti-obesity Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Anti-obesity Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Boehringer Ingelheim GmbH
Pfizer Inc.
Merck & Co. Inc.
Takeda Pharmaceuticals Company Limited
Eisai Co. Ltd.
Novo Nordisk A/S
Zafgen
Rhythm Pharmaceuticals
Zydus Cadila
Norgine B.V.
Vivus Therapeutics
Arena Pharmaceuticals Inc.
Orexigen Therapeutics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bymdtq

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets